跳转至内容
Merck
CN

SML1103

Sigma-Aldrich

恩替卡韦

≥98% (HPLC)

别名:

2-氨基-1,9-二氢-9-[（1S，3R，4S）-4-羟基-3-（羟甲基）-2-亚甲基环戊基] -6H-嘌呤-6-酮, 2-氨基-9-[（（1S，3R，4S）-4-羟基-3-羟甲基-2-亚甲基-环戊基] -3,9-二氢嘌呤-6-酮, BMS 200475, SQ 34,676

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C12H15N5O3
CAS Number:
142217-69-4
分子量:
277.28
MDL编号:
MFCD11046562
UNSPSC代码:
51111800
PubChem化学物质编号:
329825478
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

100

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D +25 to +40°, c = 0.2 in H2O

储存条件

desiccated

颜色

white to beige

溶解性

H2O: 0.5 mg/mL, clear (warmed)

储存温度

−20°C

SMILES字符串

O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1

InChI

1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1

InChI key

QDGZDCVAUDNJFG-FXQIFTODSA-N

相关类别

生化/生理作用

恩替卡韦是一种抗病毒鸟嘌呤类似物，可在病毒复制过程中抑制逆转录、DNA复制和转录。 恩替卡韦可用于治疗乙型肝炎。
恩替卡韦是一种抗病毒鸟嘌呤类似物，可抑制逆转录、DNA复制和转录。
恩替卡韦被用作治疗慢性乙型肝炎病毒（CHB）携带的拉米夫定难治性患者的有效药物（每日1 mg剂量）。

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Warning

危险声明

H302,H351

危险分类

Acute Tox. 4 Oral - Carc. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000341185
0000341185
0000397849
0000283684
0000245721

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Philip Rosenthal et al.
Hepatology (Baltimore, Md.), 69(6), 2326-2337 (2018-10-16)
The optimal management strategy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children
Amir Shlomai et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(33), 12193-12198 (2014-08-06)
Hepatitis B virus (HBV) chronically infects 400 million people worldwide and is a leading driver of end-stage liver disease and liver cancer. Research into the biology and treatment of HBV requires an in vitro cell-culture system that supports the infection
Masashi Iwamoto et al.
Scientific reports, 7(1), 10620-10620 (2017-09-08)
Viruses exploit host factors and environment for their efficient replication. The virus-host interaction mechanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely unknown. Here, a single cell cloning revealed that HepAD38 cells, a widely-used HBV-inducible cell
Lei Jiang et al.
PloS one, 11(1), e0147440-e0147440 (2016-01-23)
Nucleoside analogues (NAs) have been the most frequently used treatment option for chronic hepatitis B patients. However, they may have genotoxic potentials due to their interference with nucleic acid metabolism. Entecavir, a deoxyguanosine analog, is one of the most widely
Li-Ting He et al.
World journal of gastroenterology, 22(46), 10210-10218 (2016-12-29)
To investigate the efficacy of switching to pegylated interferon-α-2a (PegIFNα-2a) treatment in nucleos(t)ide analog (NA)-treated chronic hepatitis B (CHB) responder patients. A 48-wk prospective and retrospective treatment trial of NA-treated CHB patients who had received entecavir (ETV) for at least
查看所有相关文献

商品

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持